OBR Daily Commentary - Breast

forumImage

Brain Microenvironment Makes HER2-positive Breast Cancer Metastases Resistant to Treatment

(Mass General) May 24, 2017 - While target therapies directed toward genetic mutations that drive a tumor’s growth have significantly improved the outlook for many patients, they have not been as successful in controlling brain metastases in several types of cancer.

isac i schnirer (Posted: May 26, 2017)

quotesit's not more resistance to treatment ,but the anti her2 drugs probably don't penetrate well the bbb,including the small molecule .quotes

Read Article arrow
Add Comment 1 Comment
forumImage

Survivors of Breast Cancer Differ on Who Should Manage Follow-Up Care

(NCI/Cancer Currents Blog) Aug 2, 2017 - A new study affirms the concerns and confusion that some cancer survivors have voiced about which health care providers should be directing their long-term care.

Thomas Marsland, MD (Posted: August 08, 2017)

quotesI would tend to agree that the oncologist generally should be the one to deliver long term follow up care. There really are several reasons for this. The patient and the oncologist develop a generally intense relationship during the times of active disease and treatments. The level of trust and communication is often more than that experienced in other settings. Also we in the oncology field tend to be more available to our active patients who many times need to be seen acutely and cannot wait for delayed appointments. These carry over as patients transition into survivorship care. There is just that level of comfort for all parties. In addition it always made my day to see Ms Jones my 20 year breast cancer survivor; it is important for us as the care givers to experience the success stories too. All this is not to say others cannot provide this longer term care but at least for me I would definitely be missing something..... quotes

Read Article arrow
Add Comment 1 Comment
forumImage

Sneak Peek Into the ESMO 2017 Press Program

(ESMO) August 11, 2017 - ESMO 2017 is once again the place to be for breaking news on cancer research. ESMO 2017, the annual oncology congress organised by the European Society for Medical Oncology (ESMO) in partnership with the European Association for Cancer Research (EACR) will take place in Madrid, Spain, from 8 to 12 September at IFEMA, Feria de Madrid.

H. Jack West, MD (Posted: August 14, 2017)

quotesIt appears that while the PACIFIC trial of durvalumab consolidation after chemoradiation is being presented at ESMO, we won't see data from either the MYSTIC trial (durvalumab/tremelimumab or durvalumab monotherapy vs. chemo doublet first line for advanced NSCLC) or FLAURA (first line osimertinib vs. erlotinib or gefitinib for EGFR mutation-positive advanced NSCLC). We knew MYSTIC is negative for a PFS benefit, so we should perhaps not be surprised that AZ isn't eager to highlight the results, but I think if there were anything favorable to mitigate the disappointment, they'd have tried to stanch the bleeding by presenting the data. I suspect there will be little to encourage us when AZ ultimately deigns to show us real data. More notable is the omission of FLAURA from the ESMO program, a trial reported as positive for a significant improvement in the primary endpoint of PFS that could potentially change practice and broaden the indication for osimertinib to include first line treatment if the PFS benefit is substantial enough. Unless AZ just doesn't want to compete for the limelight with the PACIFIC trial that will likely cause a Beatlemania-reminiscent hysteria by both being an immunotherapy and being positive, this suggests that the results aren't as captivating as some would have hoped. As an alternative, the IASLC may have promised the moon and the stars to AZ to postpone presentation of a high-impact trial for the first time at the World Conference on Lung Cancer, but I would have anticipated that AZ should want to get positive results out on a potentially practice-changing therapy to as broad an audience as possible, as quickly as possible. We'll eventually see what the data show, but I'm disappointed that two of three important lung cancer trials from which we've heard initial results from recent press releases apparently won't be presented at ESMO. Makes you wonder why they're dragging their feet.quotes

Read Article arrow
Add Comment 2 Comment

Meet the Editorial Board

Community Oncology
member photo
Dean Gesme, MD

FACP FACPE FASCO President, Minnesota Oncology...

Breast Cancer
member photo
Debu Tripathy, MD

Professor and Chair, Department of Breast Medical Oncol...

Lung Cancer
member photo
H. Jack West, MD

Medical Director, Thoracic Oncology Program, Swedish Ca...

Gastrointestinal Cancers
member photo
Howard S. Hochster, MD

Distinguished Professor of Medicine, Rutgers Robert Woo...

Radiation Oncology
member photo
Howard Sandler, MD, MS, FASTRO

Ronald H. Bloom Chair in Cancer Therapeutics
Pr...

Community Oncology
member photo
Jeff Patton, M.D.

CEO Tennessee Oncology...

Precision Medicine Section Editor
member photo
Jennifer Levin Carter, MD, MPH

Chief Medical Officer and Founder, N-of-One...

Financial Sector
member photo
Michael G. King Jr.

Managing Director and Senior Biotechnology Analyst...

Gastrointestinal Cancers
member photo
Richard Goldberg, MD

Director WVU Cancer Institute Director of Cancer Signa...

Editor-In-Chief
member photo
Robert A. Figlin, MD., FACP

Professor and Director, Division of Hematology Oncology...

Health Policy
member photo
Ted Okon

Executive Director Community Oncology Alliance...

Community Oncology
member photo
Thomas Marsland, MD

Vice President Integrated Community Oncology Network ...

Community Oncology
member photo
William Harwin MD

Florida Cancer Specialists President and Managing Part...

Health Policy
member photo
William McGivney, PhD

National Health Policy Expert...

Payer
member photo
Winston Wong, PharmD

President, W-Squared Group...